Suzan Vrijaldenhoven

70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age

Martine Piccart, Laura van ‘t Veer, Coralie Poncet et al. · The Lancet Oncology · 2021 · 358 citations · Full text

Life Sciences, Biostatistics, Oncology +13

Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial

Stefanie de Groot, Rieneke T. Lugtenberg, Danielle Cohen et al. · Nature Communications · 2020 · 335 citations · Full text

Medicine, Nutritional Sciences, Oncology +17

Prognostic Significance of Macrophage Infiltration in Leiomyosarcomas

Cheng‐Han Lee, Íñigo Espinosa, Suzan Vrijaldenhoven et al. · Clinical Cancer Research · 2008 · 169 citations

Medicine, Oncology, Pathology +17

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Thomas Bachelot, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2019 · 113 citations · Full text

Medicine, Oncology, Pharmacology +17

Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC).

Gabe S. Sonke, Annemiek van Ommen‐Nijhof, Noor Wortelboer et al. · Journal of Clinical Oncology · 2023 · 91 citations

Pharmacy, Endocrinology, Oncology +10